Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:
“Wouldn’t it be nice to have a biomarker that could help identify patients most likely to benefit from T-DXd?
Earlier this year, we published a pilot study in npj Precision Oncology exploring quantitative HER2 testing to predict T-DXd, with promising results:
Title: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Authors: Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick, Kalie Smith, Fara Brasó-Maristany, Nay Nwe Nyein Chan, Laia Paré Brunet, Laura Alder, Diana Garcia-Cortes, Jorge Gomez Tejeda Zanudo, Alyssa M. Pereslete, Laura Noteware, Heather Moore, Amanda E. D. Van Swearingen, Tianyu Li, Hersh Gupta, Olivia D’Amico, Alba Martini, Stefania Morganti, Jennifer Spindel, Charmaine Cook, Christine McLaughlin, Kathrin Dvir, Ana C. Garrido-Castro, Sarah Sammons, Janet Files, Kerry Sendrick, Simone Buck, Deborah Dillon, Rinath Jeselsohn, Yvonne Y. Li, Andrew D. Cherniack, Patricia LoRusso, Maryam Lustberg, Rosario Vega-León, Francisco Pardo, Justin Davis, Claudius Mueller, Brian Corgiat, Giuseppe Curigliano, Carey K. Anders, Emanuel F. Petricoin, David L. Rimm, Aleix Prat, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney.
Excited to present the validation of the High-Sensitivity (HS)-HER2 findings at SABCS26, during Rapid Fire Oral Session 3!
One step closer to understanding which patients are most likely to benefit from T-DXd.”
Read more: Rapid Fire 3.
You can also read: A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer.
